A reader questioned a discrepancy between the financial interests disclosed in an article that I published in 20061 and my recent Archives article2 in which I revealed no financial interests. In the prior article, I disclosed grant support from Janssen for a clinical trial of risperidol in autism completed in 2003, some academic lectures sponsored by AstraZeneca, and a consultation with Shire Pharmaceuticals, all in 2004. I did not disclose these financial interests in the Archives article because they were not relevant to the subject of the article. The article reported on the longitudinal course of preschool depression and made no recommendations about treatment. Furthermore, my program of research has not supported the use of antidepressants in preschool depression and none of these pharmaceutical companies market antidepressant drugs. However, as some feel that any financial relationships with a pharmaceutical company imply a potential conflict of interest, I wish to bring these past financial relationships to the attention of the readers.
Luby JL. Matters Arising. Arch Gen Psychiatry. 2010;67(3):311. doi:10.1001/archgenpsychiatry.2010.12